Quantitative Evaluation of Seborrheic Dermatitis in Patients with Autonomic Dysfunction.
Objective: We quantitatively evaluated skin condition of patients with autonomic dysfunction. Background: Dyshidrosis are known to be one of autonomic symptom in Lewy body disease…Gut microbiota dysbiosis in Parkinson’s disease patients: a potential biomarker of disease severity and progression?
Objective: To investigate gut microbiota alterations in Parkinson's disease (PD) along disease progression. Background: Gut microbiota dysbiosis is considered a hallmark in PD1. However, it is…Underutilization of Neurology and Rehabilitation Services among People with Parkinson’s Disease
Objective: to map utilization of neurology and rehabilitation services by people with Parkinson’s disease (PD), and to identify associations between utilization and demographics. Background: People…Safety and efficacy of P2B001 (low dose combination of extended-release pramipexole and rasagiline) in patients with early Parkinson’s disease: Subgroup analyses from a randomized, controlled trial
Objective: Evaluate the efficacy and safety of P2B001 for different subgroups of patients with early Parkinson’s disease (PD). Background: P2B001 is an investigational, fixed low-dose,…Why is HAL effective in improving gait and balance function in Parkinson’s disease?
Objective: We performed rehabilitation using a Hybrid Assisted Limb (HAL) for PD and found that gait and balance functions improved before and after HAL rehabilitation.…Fecal tyrosine decarboxylase and motor response complications in Parkinson’s Disease
Objective: To investigate the clinical correlates of gut microbe-derived tyrosine decarboxylase (tdc) and motor dysfunction in Parkinson’s Disease (PD) patients. Background: Gut microbe-derived tdc was…The role of the glymphatic system on the severity and distribution of alpha-synuclein pathology in alpha-synuclein fibril induced rat model of Parkinson’s disease
Objective: The aim of this study is to investigate the contribution of the glymphatic system to the pathophysiology of Parkinson's disease (PD). Background: Neurotoxicity of…Clozapine Therapy for Parkinson’s Disease Psychosis: A 21-Year Service Analysis
Objective: To review the demographic aspects, safety, and efficacy of Clozapine treatment for Parkinson’s Disease Psychosis (PDP) in a large patient cohort. Background: The impact…The East London Parkinson Disease Project – preliminary results from a diverse population
Objective: The East London Parkinson Disease (ELPD) project is a platform study to understand the manifestations and determinants of PD in a diverse population. Background:…Effects of NE3107 anti-inflammatory treatment on motor activity and neurodegenerative features of Parkinson’s disease in a marmoset monkey model
Objective: To demonstrate the effects of an oral, anti-inflammatory agent, NE3107, on motor activity, levodopa-induced dyskinesia (LID) induction, and neuron survival in a marmoset model…
- « Previous Page
- 1
- …
- 163
- 164
- 165
- 166
- 167
- …
- 338
- Next Page »